Work in the Philip Smith Lab explores several key topics within the field of sleep medicine. We investigate the role of obesity and neural control in sleep-disordered breathing as well as the impact of metabolic function on sleep apnea. We also research the ways in which HIV and its treatments impact a patient’s sleep. Our studies have included the effects of HIV and highly active antiretroviral therapy (HAART) on both sleep and daytime function as well as the relationship between systemic inflammation and sleep apnea in men with HIV.

The Philip Wong Lab seeks to understand the molecular mechanisms and identification of new therapeutic targets of neurodegenerative diseases, particularly Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Taking advantage of discoveries of genes linked to these diseases (mutant APP and PS in familial AD and mutant SOD1, dynactin p150glued ALS4and ALS2 in familial ALS), our laboratory is taking a molecular/cellular approach, including transgenic, gene targeting and RNAi strategies in mice, to develop models that facilitate our understanding of pathogenesis of disease and the identification and validation of novel targets for mechanism-based therapeutics. Significantly, these mouse models are instrumental for study of disease mechanisms, as well as for design and testing of therapeutic strategies for AD and ALS.

Research in the Photini Sinnis Lab explores the fundamental biology of the pre-erythrocytic stages of malaria. Our team is focused on the sporozoite stage of Plasmodium, which is the infective stage of the malaria parasite, and the liver stages into which they develop. We use classic biochemistry, mutational analysis, and in vitro and in vivo assays to better understand the molecular interactions between the parasite and its mosquito and mammalian hosts. Our goal is to translate our findings to help develop treatments and a vaccine that target the malaria parasite.

The Pilot and Exploratory Studies Core supports pilot and exploratory studies related to developing effective prevention of and therapies for frailty in older adults. Our objective is to facilitate independence in older adults. We provide funding; access to biostatistical, biological and clinical research core resources; and mentoring and oversight to completion of pilot and exploratory studies.

Dr. Williams' research focuses on platelet physiology particularly as it relates to acute coronary syndromes and depression. Her laboratory specifically examines platelet aggregation, flow cytometric analysis to measure platelet activation, platelet luminescence as a measure of the platelet release reaction, many Elisa preparations in order to measure platelet function, platelet genotyping to determine the presence of certain platelet polymorphisms, and various other assays to distinguish mechanisms of platelet dysfunction. The goal for her cardiovascular platelet laboratory is to identify the etiology of platelet dysfunction in many disease states and apply methods that may improve this dysfunction that can eventually be translated to therapies for patients with cardiovascular disease. Scientific techniques performed in the lab include: flow cytometric analysis, platelet microparticle identification, and protein immunoprecipitation among other techniques.

The Pluznick Lab is interested in the role that chemosensation plays in regulating physiological processes, particularly in the kidney and the cardiovascular system. We have found that sensory receptors (olfactory receptors, taste receptors, and other G-protein coupled receptors) are expressed in the kidney and in blood vessels, and that individual receptors play functional roles in whole-animal physiology. We are currently working to identify the full complement of sensory receptors found in the kidney, and are working to understand the role that each receptor plays in whole-animal physiology by using a variety of in vitro (receptor localization, ligand screening) and in vivo (whole-animal physiology) techniques.

The Post Lab is involved in the Multi-Ethnic Study of Atherosclerosis (MESA), a collaborative study of the characteristics of subclinical cardiovascular disease (that is, disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. As MESA researchers, we study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Approximately 38 percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United States, including Johns Hopkins University. Each participant received an extensive physical exam to determine a number of conditions, including coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits have allowed study of the progression of disease. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. Wendy S. Post, MD, MS, is an associate faculty, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, and a professor of medicine.

Psychiatric Neuroimaging (PNI) is active in neuropsychiatric research using imaging methods such as MRI, fMRI, PET and DTI to understand the mechanisms and brain networks underlying human cognition. PNI faculty have published hundreds of papers on a variety of brain disorders which include but are not limited to Alzheimer's disease, Parkinson's disease, bipolar disorder, and eating disorders. Faculty in the division have been awarded numerous peer-reviewed grants by the National Institutes of Health, foundations and other funding organizations.

The Jia lab performs basic and translational research into the mechanisms of and therapeutic strategy for viral and bacterial infection-induced inflammatory lung diseases, one of the leading causes of death in pulmonary diseases, especially for the ongoing pandemic of the SARS-CoV-2 mediated COVID-19. Our work has identified novel roles of Angiotensin-converting enzyme 2 (ACE2) in the inflammatory response to viral and bacterial lung infection and its complex contributions into the pathogenesis and disease progression and outcome of COVID-19. In seeking to translate these findings to clinical studies, we have been working on a collaboration with other investigators, developing novel diagnostic, preventive, and therapeutic tools in combating the devastating COVID-19, even in the era of effective vaccine prevention. These studies are funded by NIAID.

The primary area of statistical expertise in the Qian-Li Xue Lab is the development and application of statistical methods for: (1) handling the truncation of information on underlying or unobservable outcomes (e.g., disability) as a result of screening, (2) missing data, including outcome (e.g., frailty) censoring by a competing risk (e.g., mortality) and (3) trajectory analysis of multivariate outcomes. Other areas of methodologic research interests include multivariate, latent variable models. In Women's Health and Aging Studies, we have closely collaborated with scientific investigators on the design and analysis of longitudinal data relating biomarkers of inflammation, hormonal dysregulation and micronutrient deficiencies to the development and progression of frailty and disability, as well as characterizing the natural history of change in cognitive and physical function over time.